123 related articles for article (PubMed ID: 16200638)
1. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma.
Reddy CD; Patti R; Guttapalli A; Maris JM; Yanamandra N; Rachamallu A; Sutton LN; Phillips PC; Posner GH
J Cell Biochem; 2006 Jan; 97(1):198-206. PubMed ID: 16200638
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
[TBL] [Abstract][Full Text] [Related]
3. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
Aparna R; Subhashini J; Roy KR; Reddy GS; Robinson M; Uskokovic MR; Venkateswara Reddy G; Reddanna P
J Cell Biochem; 2008 Aug; 104(5):1832-42. PubMed ID: 18348265
[TBL] [Abstract][Full Text] [Related]
5. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
6. Low-calcemic, efficacious, 1alpha,25-dihydroxyvitamin D3 analog QW-1624F2-2: calcemic dose-response determination, preclinical genotoxicity testing, and revision of A-ring stereochemistry.
Posner GH; Jeon HB; Sarjeant A; Riccio ES; Doppalapudi RS; Kapetanovic IM; Saha U; Dolan P; Kensler TW
Steroids; 2004; 69(11-12):757-62. PubMed ID: 15579327
[TBL] [Abstract][Full Text] [Related]
7. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft.
Evans SR; Schwartz AM; Shchepotin EI; Uskokovic M; Shchepotin IB
Clin Cancer Res; 1998 Nov; 4(11):2869-76. PubMed ID: 9829754
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.
Ghous Z; Akhter J; Pourgholami MH; Morris DL
Anticancer Res; 2008; 28(6A):3757-61. PubMed ID: 19189661
[TBL] [Abstract][Full Text] [Related]
10. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice.
Blutt SE; Polek TC; Stewart LV; Kattan MW; Weigel NL
Cancer Res; 2000 Feb; 60(4):779-82. PubMed ID: 10706079
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy.
Hofer H; Ho Gm; Peterlik M; Uskokovic MR; Lee JK; White MC; Posner GH; Cross HS
J Pharmacol Exp Ther; 1999 Nov; 291(2):450-5. PubMed ID: 10525058
[TBL] [Abstract][Full Text] [Related]
13. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Vegesna V; O'Kelly J; Said J; Uskokovic M; Binderup L; Koeffle HP
Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
[TBL] [Abstract][Full Text] [Related]
14. The influence of 1,25-dihydroxyvitamin D3 and 1,24-dihydroxyvitamin D3 on alphavbeta3 integrin expression in cancer cell lines.
Wietrzyk J; Filip B; Milczarek M; Klopotowska D; Maciejewska M; Dabrowska K; Kurzepa A; Dzimira S; Madej J; Kutner A
Oncol Rep; 2008 Oct; 20(4):941-52. PubMed ID: 18813838
[TBL] [Abstract][Full Text] [Related]
15. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.
Yoon JS; Kim JY; Park HK; Kim ES; Ahn KS; Yoon SS; Cho CG; Kim BK; Lee YY
Int J Oncol; 2008 Feb; 32(2):387-96. PubMed ID: 18202761
[TBL] [Abstract][Full Text] [Related]
16. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer.
El Abdaimi K; Papavasiliou V; Rabbani SA; Rhim JS; Goltzman D; Kremer R
Cancer Res; 1999 Jul; 59(14):3325-8. PubMed ID: 10416587
[TBL] [Abstract][Full Text] [Related]
17. Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation.
Peleg S; Petersen KS; Suh BC; Dolan P; Agoston ES; Kensler TW; Posner GH
J Med Chem; 2006 Dec; 49(25):7513-7. PubMed ID: 17149880
[TBL] [Abstract][Full Text] [Related]
18. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
20. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs.
Dixon KM; Deo SS; Wong G; Slater M; Norman AW; Bishop JE; Posner GH; Ishizuka S; Halliday GM; Reeve VE; Mason RS
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):137-43. PubMed ID: 16039116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
